ONE-PEAK
6.12.2022 11:15:36 CET | Business Wire | Press release
One Peak, a leading investor for growth stage B2B software companies in Europe and Israel, is excited to announce the closing of One Peak Growth III at its hard cap of $1 billion. The fund was significantly oversubscribed, demonstrating strong LP demand. Building on the success of One Peak’s first two funds, the closing of One Peak Growth III brings the firm’s total assets under management to c. $2 billion. The size of the new fund makes One Peak, founded by David Klein and Humbert de Liedekerke Beaufort, the largest fund in Europe dedicated to backing fast growing B2B software companies in the $15m-$100m investment range.
Accelerating Growth
Humbert de Liedekerke Beaufort, Co-founder and Managing Partner, said: “Growth equity is a significantly underrepresented asset class in Europe versus the US and China. There are many world class founders in Europe who need capital and support to win at global scale, and One Peak fills that gap for the best B2B software companies. With Fund III, we’ll continue to partner with the most ambitious founders and support them with our sector expertise, global network, and value creation platform to build enduring companies against the backdrop of today’s macroeconomic headwinds. $15-100m is our investment sweet spot, where we act as a catalyst to accelerate growth and help companies realize their full potential.”
Deep B2B Sector Expertise
Over the past 8 years, One Peak has built a concentrated portfolio of minority stakes in category leading software companies such as Cymulate, Deepki, DocPlanner, PandaDoc, Neo4j, and Spryker Systems. The One Peak team is an active partner to the founders it backs and supports them in building lasting, category-defining companies for the long term. This includes access to some of the best B2B software operators in the world through One Peak’s Value Creation Team which is comprised of experts in sales, marketing, partnerships, product, tech, and talent.
David Klein, Co-founder and Managing Partner, said: “We are ultimately in the business of investing in exceptional founders, and we work alongside them with the same passion and dedication as they do. Our value-add is significantly enhanced by our fully integrated Value Creation Team, particularly when it comes to hiring the best talent, accelerating top line growth, driving global expansion, and improving product and technology capabilities. This is a key differentiator for our portfolio companies in building generational companies. Last but not least, we are grateful to our founders and LPs from around the globe for their continued trust.”
One Peak’s relationship-driven approach is augmented by PULSE, One Peak’s proprietary sourcing and business intelligence software platform. PULSE integrates with a plethora of data sources and continuously surfaces the most promising opportunities for new investments and bolt-on acquisitions for One Peak’s portfolio companies.
Strong Blue Chip Investor Base
Commitments to One Peak Growth III came from a diverse group of investors from the US and Europe, including blue chip university endowments, foundations, public pensions plans, insurance companies, asset managers, fund of funds, and family offices.
Proskauer Rose LLP and Van Campen Liem served as fund counsel to One Peak Growth III.
— Ends —
About One Peak
One Peak is a leading growth equity investment firm with approx. $2 billion in assets under management that invests in technology companies in the scale-up phase. One Peak provides growth capital, operating expertise and access to its extensive network to exceptional entrepreneurs, with a view to help transform innovative and rapidly growing businesses into lasting, category-defining leaders. One Peak’s investments include Ardoq, Brightflag, Coople, Cymulate, DataGuard, Deepki, DocPlanner, Emnify, HighQ, Infermedica, Keepit, Lucca, Neo4j, Orgvue, PandaDoc, Paysend, Quentic, Spryker Systems, and many more. To learn more, visit www.onepeak.tech.
Founder testimonials
“From the early days of our relationship, One Peak worked collaboratively with us to identify growth initiatives with the biggest impact. They helped us with revenue optimization, international expansion, M&A and the recruitment of world class talent. Above all, we really value the open and direct communication and are grateful for their trust, hard work, dedication, and passion to help us realize our vision.”
Mariusz Gralewski, Founder & CEO, DocPlanner
“One Peak has been a true value-add partner to us since day 1. They really are one of those rare investors that can zoom in and zoom out, talk big picture strategy and nitty-gritty operational details, and add value on the go-to-market side as well as challenge our thinking on product. Plus they are driven, passionate, have great clarity of thought, and are simply nice people – we genuinely enjoy the great cultural fit with the One Peak team.”
Emil Eifrem, Founder and CEO, Neo4j
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
